Transgene Biotek Ltd has closed its trading window for all insiders and designated persons effective July 1, 2026, to comply with regulatory norms ahead of its quarterly financial announcement. The restriction prevents trading in the company's securities until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. This measure is mandated by the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the company's internal code of conduct.

The closure applies to all insiders and designated persons, including their immediate relatives, as defined in the company's Prohibition of Insider Trading Code. The trading window will reopen only after the stipulated period following the results declaration. The specific date for the board meeting to consider and declare the unaudited financial results for the first quarter ending June 30, 2026, has not yet been announced and will be intimated in due course.

Key Details

The company's decision aligns with standard market practices to ensure fairness and prevent potential insider trading during the sensitive period surrounding financial disclosures.

Transgene Biotek reported a widened net loss of ₹16.53 crore for the financial year ended March 31, 2026, compared to a net loss of ₹6.76 crore in the previous year. The loss was primarily driven by a surge in finance costs to ₹10.60 crore in FY26 from ₹2.43 crore in the prior year. Revenue from operations fell to ₹2.11 crore in FY26 from ₹2.61 crore in FY25, while total income dropped to ₹3.61 crore from ₹10.44 crore. The company's equity share capital remained constant at ₹757.70 lakh.

The Board of Directors approved the audited financial results for the fourth quarter and financial year ended March 31, 2026, at a meeting held on May 29, 2026. M/s. Vasavi & Co, Chartered Accountants, issued an Independent Auditors' Report with an unmodified opinion on both the standalone and consolidated financial results. The auditors confirmed that the results give a true and fair view of the company's financial position in conformity with Indian accounting standards.

Financial Performance

For the quarter ended March 31, 2026, the company reported a net loss of ₹4.57 crore, compared to a net loss of ₹7.13 crore in the same quarter of the previous year. Revenue from operations for the quarter stood at ₹0.55 crore, down from ₹0.77 crore in Q4 FY25. Total expenses for the quarter were ₹6.61 crore, a decrease from ₹8.33 crore in the corresponding prior period.

The basic and diluted earnings per share (EPS) for FY26 were reported at a loss of ₹0.22 per share, compared to a loss of ₹0.09 per share in FY25.

Standalone Financial Results

The following table summarizes the standalone financial performance for the year ended March 31, 2026:

Consolidated Financial Results

The consolidated financial results for the year ended March 31, 2026, mirrored the standalone figures, with a net loss of ₹16.53 crore on a total income of ₹3.61 crore. The consolidated results include the financials of Transgene Biotech HK Ltd, a subsidiary that has not been in operations for many years. The auditors noted that the subsidiary's books of accounts have not been audited recently, and the last available figures from 2015-16 are being carried forward for consolidation.

Asset and Liability Position

As of March 31, 2026, the company's total assets stood at ₹33.76 crore, a decrease from ₹34.20 crore in the previous year. Non-current assets were ₹32.75 crore, while current assets were ₹1.02 crore. Total equity and liabilities amounted to ₹33.76 crore, with equity showing a negative balance of ₹9.20 crore. Non-current liabilities were ₹29.82 crore, and current liabilities were ₹13.14 crore.

Cash and cash equivalents decreased to ₹0.61 crore as of March 31, 2026, from ₹2.84 crore in the prior year. The net cash flow from operating activities was negative at ₹0.11 lakh, compared to a positive flow of ₹11.96 lakh in FY25.